ICUI
ICU Medical, Inc.
NASDAQ · Healthcare · Medical - Instruments & Supplies · US
$167.58
+0.78%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 2.2B | 2.2B | 2.4B | 2.3B | 2.3B |
| Cost of Revenue | 1.3B | 1.4B | 1.6B | 1.5B | 1.6B |
| Gross Profit | 811.2M | 819.7M | 824.8M | 739.9M | 697.8M |
| Operating Expenses | |||||
| R&D Expense | 86.3M | 87.5M | 88.6M | 85.3M | 93.0M |
| SG&A Expense | 615.1M | 625.2M | 638.8M | 606.7M | 608.3M |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 1.0M | — | 54.4M | 25.0M | 39.3M |
| Total Operating Expenses | 702.4M | 712.7M | 781.8M | 717.0M | 740.7M |
| Cost and Expenses | 2.1B | 2.1B | 2.3B | 2.2B | 2.3B |
| Operating Income (EBIT) | 108.8M | 107.0M | 43.0M | 22.8M | (42.9M) |
| Non-Operating | |||||
| Interest Income | 7.0M | 10.3M | 10.8M | 7.5M | 4.4M |
| Interest Expense | 83.0M | 105.4M | 106.5M | 102.7M | 70.8M |
| Net Interest Income | (76.0M) | (95.1M) | (95.8M) | (95.2M) | (66.4M) |
| Other Non-Op Income/Expense | (112.6M) | (103.8M) | (109.0M) | (101.1M) | (71.5M) |
| Non-Operating Income (excl Interest) | 65.9M | (1.6M) | 2.4M | (1.6M) | 706.0K |
| EBT (Pre-Tax Income) | (3.9M) | 3.2M | (66.0M) | (78.3M) | (114.4M) |
| Income Tax Expense | (31.0M) | 2.4M | 51.7M | (48.6M) | (40.1M) |
| Bottom Line | |||||
| Net Income | 30.1M | 732.0K | (117.7M) | (29.7M) | (74.3M) |
| Earnings from Cont. Ops | 27.1M | 732.0K | (117.7M) | (29.7M) | (74.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 30.1M | 732.0K | (117.7M) | (29.7M) | (74.3M) |
| Per Share | |||||
| Basic EPS | $1.20 | $0.03 | ($4.83) | ($1.23) | ($3.11) |
| Diluted EPS | $1.18 | $0.03 | ($4.83) | ($1.23) | ($3.11) |
| Revenue Per Share | $86.37 | $90.50 | $97.67 | $93.77 | $95.53 |
| Shares | |||||
| Basic Shares Outstanding | 25.0M | 24.6M | 24.4M | 24.1M | 23.9M |
| Diluted Shares Outstanding | 25.0M | 24.9M | 24.4M | 24.1M | 23.9M |
| Profitability Metrics | |||||
| EBITDA | 297.6M | 326.5M | 43.0M | 253.2M | 191.5M |
| D&A | 254.8M | 218.0M | 2.4M | 228.8M | 235.2M |
| EBIT | 42.8M | 108.5M | 40.5M | 24.4M | (43.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026